Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Expands By 66.2%

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,650,000 shares, an increase of 66.2% from the August 31st total of 992,900 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average trading volume of 714,400 shares, the short-interest ratio is presently 2.3 days.

Wall Street Analyst Weigh In

ATHA has been the topic of several research reports. BTIG Research lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. JMP Securities downgraded Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th. Mizuho downgraded Athira Pharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $5.00 to $0.50 in a research report on Thursday, September 19th. Finally, Rodman & Renshaw lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ATHA. Rothschild Investment LLC purchased a new stake in Athira Pharma in the second quarter valued at approximately $34,000. Mirador Capital Partners LP purchased a new stake in shares of Athira Pharma during the 1st quarter valued at $57,000. XTX Topco Ltd acquired a new stake in shares of Athira Pharma during the 2nd quarter worth $60,000. Invst LLC purchased a new position in shares of Athira Pharma in the 2nd quarter worth $68,000. Finally, Forefront Analytics LLC boosted its holdings in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares during the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Stock Performance

ATHA stock opened at $0.44 on Thursday. Athira Pharma has a one year low of $0.41 and a one year high of $4.30. The stock has a market capitalization of $16.79 million, a P/E ratio of -0.14 and a beta of 2.90. The company has a 50 day moving average price of $2.31 and a two-hundred day moving average price of $2.43.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. Research analysts forecast that Athira Pharma will post -2.57 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.